Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo

Title:Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo

Volume: 21 Issue: 13

Author(s): Mengli Wang, Qiuzheng Du, Lihua Zuo, Peng Xue, Chao Lan* Zhi Sun*

Affiliation:

• Department of Emergency Intensive Care Unit, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan,China

• Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan,China

Keywords: Tumor, targeting drug, metabolism, distribution, pharmacokinetics, kinase inhibitors.

Abstract: Background: As a new tumor therapy, targeted therapy is becoming a hot topic due to its high efficiency and low toxicity. Drug effects of targeted tumor drugs are closely related to pharmacokinetics, so it is important to understand their distribution and metabolism in vivo.

Methods: A systematic review of the literature on the metabolism and distribution of targeted drugs over the past 20 years was conducted, and the pharmacokinetic parameters of approved targeted drugs were summarized in combination with the FDA's drug instructions. Targeting drugs are divided into two categories: small molecule inhibitors and monoclonal antibodies. Novel targeting drugs and their mechanisms of action, which have been developed in recent years, are summarized. The distribution and metabolic processes of each drug in the human body are reviewed.

Results: In this review, we found that the distribution and metabolism of small molecule kinase inhibitors (TKI) and monoclonal antibodies (mAb) showed different characteristics based on the differences of action mechanism and molecular characteristics. TKI absorbed rapidly (Tmax ≈ 1-4 h) and distributed in large amounts (Vd > 100 L). It was mainly oxidized and reduced by cytochrome P450 CYP3A4. However, due to the large molecular diameter, mAb was distributed to tissues slowly, and the volume of distribution was usually very low (Vd < 10 L). It was mainly hydrolyzed and metabolized into peptides and amino acids by protease hydrolysis. In addition, some of the latest drugs are still in clinical trials, and the in vivo process still needs further study.

Conclusion: According to the summary of the research progress of the existing targeting drugs, it is found that they have high specificity, but there are still deficiencies in drug resistance and safety. Therefore, the development of safer and more effective targeted drugs is the future research direction. Meanwhile, this study also provides a theoretical basis for clinical accurate drug delivery.

Cite this article as:

Wang Mengli, Du Qiuzheng, Zuo Lihua , Xue Peng , Lan Chao *, Sun Zhi *, Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo, Current Drug Metabolism 2020; 21 (13) . https://dx.doi.org/10.2174/1389200221666201112110638

DOI https://dx.doi.org/10.2174/1389200221666201112110638	Print ISSN 1389-2002
Publisher Name Bentham Science Publisher	Online ISSN 1875-5453